Anemia
Also known as: Iron poor blood, Decreased, Diminished, Inadequate, Under
Methodology & AI Transparency ⓘ
Anemia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: If you have anemia, your blood does not carry enough oxygen to the rest of your body.
- 2 Real-world patient consensus: Diagnostic registry D50.9: Anemia is managed within Blood & Anemia (aka Iron poor blood).
- 3 Typical cash cost range: Differential triage of Anemia (D50.9) utilizes individualized anticoagulation or in Anemia (D50.9: transfusion care).
- 4 Top reported side effects / signs: Key Blood & Anemia biomarkers for Anemia (D50.9): Serum Ferritin & in Anemia (D50.9: Transferrin Saturation) & Vitamin B12, Folate in Anemia (D50.9: & Reticulocyte Count) (B12 > 500 pg/mL; appropriate marrow response (D50.9)).
Ask our AI Specialists anything about Anemia
What Is Anemia?
If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron . Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body. Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction.
Pathophysiology, Underlying Causes & Clinical Presentation
Anemia (D50.9) alters blood & anemia homeostasis through primary platelet/megakaryocyte dysregulation in Anemia (D50.9: or inherited/acquired coagulation); Cross-referenced with NIH MeSH (Anemia), clinical remission targets Vitamin B12, Folate in Anemia (D50.9: & Reticulocyte Count) within B12 > 500 pg/mL; appropriate marrow response (D50.9).
Common Symptoms & Clinical Signs
- • Colon polyps or colon cancer
- • Inherited disorders
- • Presentation of Anemia (D50.9): restless legs, ice in Anemia (D50.9: craving)
- • Secondary Anemia clinical sign: easy bruising, prolonged in Anemia (D50.9: bleeding from minor)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Anemia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D50.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Ferritin & in Anemia (D50.9: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D50.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Anemia (D50.9: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D50.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Platelet Count & in Anemia (D50.9: PT/INR / aPTT) | Platelets 150–400 x10^3/uL (D50.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Anemia
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Iron, Folic Acid, Vitamin/Mineral Supplement Irospan 24/6 • RxCUI 1102196 | FDA Prescription Therapeutic Agent | 88% | $0.9800 | $ 48.19 /mo |
| Sodium Ferric Gluconate Complex Ferrlecit • RxCUI 242761 | Parenteral Iron Replacement | 94% | $6.0970 | $ 185.00 /mo |
| Mitapivat Pyrukynd, Aqvesme • RxCUI 2594473 | Pyruvate Kinase Activator | 81% | $0.3600 | $ 23.08 /mo |
| Ferrous Fumarate, Folic Acid Vitrexate Fe, Vitrexyl Plus Iron • RxCUI RXN-59088168-2006 | Vitamin B12 | 86% | $0.4900 | $ 28.34 /mo |
| Daprodustat Jesduvroq • RxCUI 2628215 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor | 88% | $0.6400 | $ 34.42 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Anemia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With: What a 5,204-Participant Study Found A total of 5204 men were included, 815 with anemia (mean [SD] age, 64.8 [7.7] years; 247 Black [30.3%], 544 White [66.7%], 24 other [2.9%]) and 4379 without anemia (mean [SD] age, 63.0 [7.9] years; 629 Black [14.4%], 3603... JAMA network open • 2023-10-02 • Randomized Controlled Trial | N = 5,204 | 96/100 | PMID 37889486 ↗ |
| New Insights on Glasdegib plus intensive or non-intensive chemotherapy for untreated acute: What a 404-Participant Study Found The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Leukemia • 2023-10-15 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 37604981 ↗ |
| New Insights on Roxadustat for the treatment of anemia in chronic kidney disease patients not on: What a 594-Participant Study Found Roxadustat demonstrated superior efficacy versus placebo in terms of both Hb response rate and change in Hb from BL. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2021-08-27 • Phase III Randomized Trial | N = 594 | 93/100 | PMID 33630072 ↗ |
| Living Longer With Bone Marrow Scarring: What 2,233 Patients Taught Doctors About Ruxolitinib Momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. Leukemia & lymphoma • 2024-07-15 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 38501751 ↗ |
| New Insights on Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic: What a 1,068-Participant Study Found Roxadustat effectively increased hemoglobin in patients with DD-CKD, with an AE profile comparable to epoetin alfa. Journal of the American Society of Nephrology : JASN • 2022-04-15 • Phase III Randomized Trial | N = 1,068 | 90/100 | PMID 35361724 ↗ |
Anemia Patient Community & “People Like Me” Threads
Filter Anemia community threads and patient logs by age, biological sex, dosage, and treatment duration.
Tracking Serum Ferritin & in Anemia (D50.9: Transferrin Saturation) every 12 weeks for Anemia: what lab cadence worked best?
FDA/PubMed Clinical Context Note: Clinical guidelines across Anemia, Clotting & Blood Disorders (Anemia, ICD-10-CM D50.9) generally pair 8-to-12-week repeat biomarker verification (Serum Ferritin & in Anemia (D50.9: Transferrin Saturation): Ferritin 50–150 ng/mL; TSAT 20%–45% (D50.9)) with symptom review so steady-state physiological response is captured accurately.
After being diagnosed with Anemia (ICD-10 D50.9), my clinician and I set a goal around Serum Ferritin & in Anemia (D50.9: Transferrin Saturation) (Ferritin 50–150 ng/mL; TSAT 20%–45% (D50.9)) before escalating medication doses. For others managing blood & anemia markers, did quarterly bloodwork catch changes early enough without over-testing?
12-week intervals worked really well for tracking Serum Ferritin & in Anemia (D50.9: Transferrin Saturation). Using the same morning fasting draw window each quarter eliminated day-to-day noise so my doctor could adjust cleanly.
Ordering Serum Ferritin & in Anemia (D50.9: Transferrin Saturation) alongside standard preventive labs prior to my follow-up visit saved an extra co-pay and kept our appointment focused on actual trend lines.